ASMLASML Holding N.V.
Industry AI semis Updated 24 Sep 2026
The idea
The EUV monopoly with a shrinking share count; at ~29x FY28 the base case is roughly priced in, and upside needs the second capacity step (+30% low-NA EUV, +30% more for 2028).
Events to watch
- Quarterly orders and 2027 capacity commentary
- whether the 'investigated' 2028 +30% is confirmed
- TSMC capex discipline as the bubble indicator
How we got the target
Scorecard: base ~$1,780 (~28.9x FY28E model EPS; converted at EUR/USD 1.14673). Time frame: FY2028.
Target: from the research notes. Prices: market data get_latest_stock_price, close of 2026-09-22 (fetched 2026-09-23)
What would prove it wrong
7 warning signsThe 2028 capacity step is dropped rather than confirmed.
Details
Management is "investigating" a second +30% for 2028 on top of the +30% already planned for 2027. ASML adds capacity only against customer commitment; withdrawing that study, or guiding 2028 capacity flat, says its customers stopped committing — quarters before any revenue line would.
Customer concentration keeps climbing.
Details
The largest customer went 16.6% → 23.9% of net sales in one year, and the top two are 38.0%. Above ~30% for a single customer and ASML is a single-customer capex proxy, whatever its monopoly.
The US 50%-ownership affiliate rule comes back on 2026-11-10.
Details
It is suspended, not repealed, and the suspension expires inside the next twelve months. Reinstatement, or any expansion of the entity list, hits 29.1% of sales directly.
Gross margin breaks below the 54% floor of the FY2026 guide.
Details
The guide is 54–56% against 52.8% delivered in 2025 and 51.3% in both 2023 and 2024. The step up is High-NA mix and installed- base upgrades; a return to ~51% would say the mix, not the volume, was the story.
Installed Base Management sales stop carrying the quarter.
Details
Q2 2026 beat guidance "driven primarily by higher than expected Installed Base Management sales" — service and field upgrades, €2,762m of €9,326m. Service revenue is the shock absorber; if it is what makes the quarters, new-system demand is softer than the headline.
The year-end backlog does not grow.
Details
ASML ended quarterly bookings after 2025 and now reports the systems backlog once a year (€38.8bn at 2025-12-31, PR-Q4-25). Management declined three times to say how much of the next year is on order while planning +30% capacity for 2027 and investigating another +30% for 2028. A 2026 year-end backlog at or below €38.8bn while 2026 sales run €43–45bn means the capacity is being built ahead of orders that are not arriving.
Receivables keep outrunning sales.
Details
Receivables were €7,252.6m at 2026-06-28 (~71 days on annualised Q2 sales, ~59 a year earlier). A third consecutive rise at Q3 2026, or operating cash flow for FY2026 below net income, turns the earnings-quality flag into a finding.
How far along
7 of 10 steps done · 3 done in a group review
Next step
watch the second capacity step. ASML has planned +30% on 2027 low-NA EUV (off ~65 units) and DUV immersion (off ~130), and is "investigating" a further 30% for 2028. The 2026-09-20 cluster file named TSMC's capacity discipline the best single bubble indicator for this complex and flagged that TSMC is not on the watchlist. ASML is the same indicator one layer up, it publishes quarterly, and it is already on the list. Whether "investigating" becomes "planning" is the disclosure to wait for; it would be the earliest credible top signal available on this source ladder.
Needs your decision
S6 product test / expert call, S7 conviction. open Open (filings): Q3 2026 results (~mid-October) score the €11–12bn / 55–57% guide; the FY2026 year-end backlog (January 2027) tests the order-coverage thread; the 2026–2028 €12bn buyback is on pace (€2.2bn in H1 2026).
Failed checks
none. S0/S4/S7 are not closed by design (cluster stages, carried forward). S3's 2026-09-21 pass had no transcript; the 2026-09-24 backfill read two from the archive. Dodge thread: how much of the out-year is on order was declined on three calls (2025-04-16, 2025-07-16, 2026-07-15), after quarterly bookings disclosure ended with 2025 — the 2028 capacity step rests on "demand signals" and, in Dassen's words on 2026-07-15, "we don't have orders for 110 EUV Low-NA at this stage." The annual backlog in the January 2027 release is the only filing that settles it. EQ flag: receivables ~71 days at Q2 2026 against ~59 a year earlier.
Who runs it
The Front OfficeStep by step
- S0How it does as AI gets cheapDone in a group review
carry-forward (cluster: AI-capex complex — cluster pass, 2026-09-20)
cluster verdict is.
⚠️ SPLIT; ASML is a seller of the shortage and funds nothing it sells into. Owner checks dropped 2026-09-21 (README §Stage 0 override).
- S1Where the idea came fromDone
watchlist (owner, Apple Stocks, 2026-09-20); no Tier 0 promotion.
- S2Quick deal-breaker checkDone
FY25 net sales €32,667.3m +15.6%, GM 52.8%, op margin 34.6%, net income €9,609.4m (29.4% of sales), backlog €46.5bn. Six straight profitable years.
Full notes
Share count DOWN 7.2% over five years (419.1m → 388.9m) on €5.95bn of 2025 buybacks — the only name in this slot whose count shrinks. Survives outright. Capital allocation (dossier-2026-09-24): 5-yr FCF €40.4bn, 79% returned (€20.65bn buybacks at ~€618 avg vs ~€1,534 today, €11.28bn dividends), M&A €34m, debt rolled (net cash ~€8.9bn at 2025-12-31), SBC 1.8% of FCF, no goodwill impairment. ROIC 31% (2020) → 87% (2025) while invested capital fell — compounds. Bonus pays on EBIT margin, rTSR, ROAIC, not EPS.
- S3Reading the company's reportsDone
(gate-minimum, FPI variant)
FY25 20-F Item 3.D risk factors and Item 5, Q2 2026 6-K results and guidance, investor presentation. Three disclosed risks named with locators. Item 4A "Not applicable" — no open SEC comments.
⚠️ (2026-09-21 pass) ZERO transcripts: Equibles has none on file for ASML FY2026 Q2 and the fool.com fallback 404'd. Every forward statement comes from the written 6-K. Proxy and insider pattern skipped — an FPI files neither. EQ: 1 flag — receivables up two quarters running (~28 → ~46 → ~71 days, +12 days YoY at Q2 2026) while sales grow; no non-GAAP add-backs (US GAAP only, IFRS is the book that capitalises development), SBC 1.8% of FCF, 3-yr OCF/NI 1.17; H1 2026 OCF −€0.5bn vs NI €5.7bn is prepayment timing (dossier-2026-09-24). Transcripts: 2026-09-24 read FY2026-Q2 and FY2025-Q2 in full from the archive (Q1/Q3 files are Q&A-free results videos).
- S4Rivals and suppliersDone in a group review
carry-forward (cluster: AI-capex complex — cluster pass, 2026-09-20)
- S5Who owns the stockDone
Equibles top holders (2,504 institutions, 2026-06-30), 13D/G census (three filings ever, all 13G/A, no activist), FINRA short interest at 0.4% of shares out, buyback and dividend. No shelf or ATM: capital flows out, not in.
⚠️ 3spread returned 2 filers / 1,185 shares for CUSIP N07059202 — the ADR gap found at ARM and OMAB, now confirmed a third time. Insider ownership % is unavailable for any sec_fpi row: no DEF 14A, no Form 4.
- S6What workers and customers sayDone
carry-forward (cluster: AI-capex complex — cluster pass 2: S6 for 41 names, S0/S4/S7 for three, 2026-09-21)
ASML is one of the ten members covered from the board's own claim rows (Dom Rizzo, 2026-08-11: "I mean, ASML is a clear linchpin example."). Product test / expert call open OPEN (user)
- S7The case for it, and pricesDone in a group review
carry-forward (cluster: AI-capex complex — cluster pass, 2026-09-20)
conviction open OPEN (user) · valuation (bear/base/bull; moved from S8 2026-09-23): 60.5x trailing, ~42.6x FY26E and ~28.9x FY28E model EPS at $1,714.68 (2026-09-21, EUR/USD 1.14673). Base case ~$1,780 — about 4% above the traded price.
Full notes
Bear ~$859, bull ~$2,436.
- S8Do the bosses keep their word?Done
23 rows: 7 beat, 13 met, 1 missed, 2 withdrawn
reliable. Current team (CEO Fouquet since 2024-04-24, CFO Dassen since 2018) made rows 1–19: every quarterly and annual sales/GM range Q3 2024–Q2 2026 met or beaten, none missed. FY2026 first guide €34–39bn raised twice to €43–45bn.
Full notes
The miss and withdrawals are the 2022 Investor Day plan (Wennink departed. Dassen co-presented): 2025 GM 54–56% walked back, €12bn buyback 63% done, 90-EUV capacity not reached. Dodge roll-up: 7 dodges/declines over three analyst calls; out-year order coverage declined in all 3 (dossier-2026-09-24).
- S9What to watch nextDone
trigger written. Tier 0 EDGAR sweep covers the feed (cik 937966)
Sources and notes
Sources 7 documents
- Full notes, 24 Sep 2026
- Full notes, 21 Sep 2026
- AI-capex complex — cluster pass, 2026-09-20
- AI-capex complex — cluster pass 2: S6 for 41 names, S0/S4/S7 for three, 2026-09-21
- EDGAR filings CIK 937966
| Short name | Document | Where it came from | Read on |
|---|---|---|---|
| 20F-FY25 | ASML 20-F for FY ended 2025-12-31, filed 2026-02-25 (incorporates the 2025 Annual Report) | https://www.sec.gov/Archives/edgar/data/937966/000162828026011378/asml-20251231.htm | 2026-09-21 |
| 6K-Q2-26 | ASML 6-K quarterly filing, 2026-07-15 — Q2 2026 press release with financial results | https://www.sec.gov/Archives/edgar/data/937966/000162828026048235/pressreleasefinancialresul.htm | 2026-09-21 |
| 13F-Q2-26-EQ | Top institutional holders by manager, 13F report date 2026-06-30 (2,504 institutions, 86.0m shares) | Equibles GetTopHolders ASML — https://equibles.com/stocks/asml/holdings | 2026-09-21 |
| 13F-Q2-26-3S | 3spread 13F holders for CUSIP N07059202 — returned 2 filers and 1,185 shares (tool gap, see note) | python ledger/research/tools/threespread.py holders ASML | 2026-09-21 |
| EDGAR-INDEX | ASML EDGAR filing index (CIK 937966) — 25 20-Fs, 361 6-Ks, no 10-K, no DEF 14A, no Form 4 | https://data.sec.gov/submissions/CIK0000937966.json | 2026-09-21 |
| ID-2022 | ASML 6-K 2022-11-10, Ex. 99.1 — 2022 Investor Day press release (2025 and 2030 scenarios, €12.0bn 2022–2025 buyback) | https://www.sec.gov/Archives/edgar/data/937966/000119312522282132/d308550dex991.htm | 2026-09-24 |
| AGM-26 | ASML 6-K 2026-04-23 — disclosure of 2026 AGM results | https://www.sec.gov/Archives/edgar/data/937966/000162828026026703/asmldiscloses2026agmresults.htm | 2026-09-24 |
Links to other companies 19 links
| From | Link | To | Date | Where it says so |
|---|---|---|---|---|
| ASML's largest customer (not named in the 20-F) | channel concentration | ASML | 2025-12-31 | 20F-FY25 — Risk – Risk factors, 'A high percentage of net sales is derived from a few customers' |
| Netherlands export-licensing authority | regulator of | ASML | 2025-12-31 | 20F-FY25 — Risk – Risk factors, export control restrictions |
| United States export-control authority | regulator of | ASML | 2025-12-31 | 20F-FY25 — Risk – Risk factors, export control restrictions; and the geopolitical developments section |
| People's Republic of China (export controls on rare earths) | supplier dependency | ASML | 2025-12-31 | 20F-FY25 — geopolitical developments section, China's Rare Earth Controls |
| ASML | channel concentration | People's Republic of China (export controls on rare earths) | 2025-12-31 | 20F-FY25 — Risk – Risk factors, international operations |
| Canon | competitor | ASML | 2025-12-31 | 20F-FY25 — Risk – Risk factors, 'We face intense competition' |
| Nikon | competitor | ASML | 2025-12-31 | 20F-FY25 — Risk – Risk factors, 'We face intense competition' |
| Applied Materials Inc. | partner and competitor | ASML | 2025-12-31 | 20F-FY25 — Risk – Risk factors, 'We face intense competition' |
| KLA-Tencor Corporation | competitor | ASML | 2025-12-31 | 20F-FY25 — Risk – Risk factors, 'We face intense competition' |
| ASML | event | ASML | 2026-07-15 | 6K-Q2-26 — CEO statement and outlook |
| ASML | governance structure | ASML | 2026-07-15 | 6K-Q2-26 — Update share buyback program and dividend |
| FMR LLC | holds | ASML | 2026-06-30 | 13F-Q2-26-EQ — row 1, FMR LLC |
| Fisher Asset Management, LLC | holds | ASML | 2026-06-30 | 13F-Q2-26-EQ — row 2, Fisher Asset Management, LLC |
| Capital World Investors | holds | ASML | 2026-06-30 | 13F-Q2-26-EQ — row 3, Capital World Investors |
| Susquehanna International Group, LLP | holds | ASML | 2026-06-30 | 13F-Q2-26-EQ — row 10, SUSQUEHANNA INTERNATIONAL GROUP, LLP, Type: Put |
| ASML | context | ASML | 2026-09-21 | 13F-Q2-26-3S — script output header: 'filers: 2 (prior 2); shares reported: 1,185' |
| Christophe D. Fouquet | officer of | ASML | 2026-02-25 | 20F-FY25 — Remuneration report, Board of Management remuneration footnote 1; Board of Management bios; signature page |
| Roger J.M. Dassen | officer of | ASML | 2026-04-23 | 20F-FY25 — Board of Management bios (Roger J.M. Dassen); signature page; re-appointment in AGM-26 |
| Peter T.F.M. Wennink | officer of | ASML | 2024-04-24 | 20F-FY25 — Remuneration report, Board of Management remuneration footnote 1 (former Board of Management); ID-2022 first paragraph for the 2022 role |
History 3 entries
- 2026-09-21 — first pass, slot
names-ai-capex-3, model-drafted unattended by the cloud research routine. S1, S2, S3 (gate-minimum, FPI variant), S5 and S9 closed; S0/S4/S7 carried forward from the 2026-09-20 cluster file and S6 from the 2026-09-21 one; S8 modelled and left open. No transcript was obtainable. Evidence and access limits in dossier-2026-09-21.md. Nothing here is human-verified. - 2026-09-23 — stage redefinition, owner decision (WATCHLIST_PLAN.md §25): S8 is now Management credibility and is not yet run for this name; the old S8 valuation figures moved to the
valuation:line under S7, and any proposed buy price or position size was removed (the pipeline no longer drafts either). No research was redone. S2 capital allocation and S3 earnings quality are also pending, in the same backfill slot. - 2026-09-24 — backfill, slot
backfill-2026-09-23-3, model-drafted by a manually started cloud session (not the routine). Added S8 management credibility (23-row say-vs-do table — reliable, ✅), S2 capital allocation (compounds; glyph unchanged) and the S3 earnings-quality check (1 flag; glyph unchanged), the dodge log (first transcripts read for this name: FY2026-Q2 and FY2025-Q2 in full), two kill criteria and three officer_of edges. S7 valuation line unchanged — S8 did not say over-promises, so no haircut. Sources: EDGAR 6-K releases, 20-F FY2025, XBRL; market data for price and FX. No Equibles calls. Evidence in dossier-2026-09-24.md. Nothing here is human-verified.
Full notes, 24 Sep 2026 21 min read
ASML — dossier, 2026-09-24 (backfill: S8, S2 capital allocation, S3 earnings quality)
Slot backfill-2026-09-23-3. Model-drafted by a manually started cloud session; nothing here is human-verified. Only the three checks added on 2026-09-23 are written here (SKILL.md §0 "Backfill slots"); every other stage stands as written in dossier-2026-09-21.md. All money is EUR unless marked; anything from background knowledge is marked [background].
Sources read this run (all via EDGAR with the ddboard-research User-Agent, except where noted):
| Key | Document | Locator used |
|---|---|---|
| PR-Q2-24 … PR-Q2-26 | the nine quarterly results press releases, Ex. 99.1 of the quarterly 6-Ks filed 2024-07-17, 2024-10-15, 2025-01-29, 2025-04-16, 2025-07-16, 2025-10-15, 2026-01-28, 2026-04-15, 2026-07-15 (pressreleasequarterlyresul.htm / pressreleasefinancialresul.htm) | headline bullets; "CEO statement and outlook"; "Update dividend and share buyback program" |
| FS-Q2-26 | Q2 2026 6-K financialstatementsusgaa.htm (accession 0001628280-26-048235) | quarterly summary balance sheet and cash-flow statement |
| ID-2022 | 6-K 2022-11-10, Ex. 99.1 d308550dex991.htm (0001193125-22-282132) — 2022 Investor Day | bullet list; "New share buyback program" |
| ID-2024 | 6-K 2024-11-14, Ex. 99.1 pressreleaseinvestorday2024.htm (0000937966-24-000024) | first paragraph; CFO quote |
| 20F-FY25 | 20-F for FY2025 (0001628280-26-011378) | Board of Management bios; Remuneration report; Note 22 Shareholders' equity (purchase table); signature page |
| AGM-26 | 6-K 2026-04-23 asmldiscloses2026agmresults.htm (0001628280-26-026703) | list of subjects discussed |
| XBRL | data.sec.gov/api/xbrl/companyfacts/CIK0000937966.json — ASML's 20-F is US GAAP, so the tags are us-gaap | concept names given inline |
| Transcripts | ledger/research/_transcripts/ASML/FY2024-Q3 … FY2026-Q2 (market data; call date per index.json) | call date; speaker label read off at the quote's position |
| market data | get_latest_stock_price NASDAQ:ASML → $1,744.61 close 2026-09-23; get_latest_forex_price FX:EURUSD → 1.13767 (2026-09-24); get_profitability_ratios FY2024–25 | — |
Price reference for this file: $1,744.61 ÷ 1.13767 = ~€1,533.5 per share (conversion, one rate).
S8 — management credibility
Who promises. Roles from the FY2025 20-F, not from context. Christophe D. Fouquet — "President, Chief Executive Officer and Chair of the Board of Management" (20F-FY25, Board of Management bios); the 20-F remuneration note says "Christophe D. Fouquet was appointed as President and CEO of ASML on April 24, 2024." Roger J.M. Dassen — "Executive Vice President and Chief Financial Officer"; "Roger Dassen joined ASML in June 2018 and was" appointed EVP, CFO and member of the Board of Management at the AGM that year (same bio block); re-appointed for a new term at the 2026 AGM (AGM-26: "The reappointment of Roger Dassen and Frédéric Schneider-Maunoury" is listed among the subjects; the 20-F Supervisory Board report says the Selection and Nomination Committee proposed a new four-year term). Both signed the 20-F on 2026-02-25. Officer edges added to relationships.yaml.
Departed check. The previous CEO is gone: "On April 24, 2024, Peter T.F.M. Wennink and Martin A. van den Brink stepped down from their roles as Presidents of ASML." (20F-FY25, remuneration report footnote). Every promise in the 2022 Investor Day release (ID-2022) was made by "President & CEO Peter Wennink and Executive Vice President & CFO Roger Dassen" — so the medium-term rows below are departed for the CEO half and current for the CFO half. No CFO or CEO change followed a miss inside the window. The CEO change (announced 2023-11-30 per the 20-F) preceded, rather than followed, the one walked-back medium-term target.
How the guide is given. Every quarterly release carries the next-quarter net sales and gross margin range and a full-year view in a paragraph quoted as said by "ASML President and Chief Executive Officer Christophe Fouquet"; on the call the CFO restates it. The written release is the first guide and the locator; the promiser is Fouquet (CEO, quoted in the release) with Dassen (CFO) as the speaker on the call. A range is scored met when the result is inside it, beat above the top (for sales and margin).
Say-vs-do table (guides made 2024-07-17 to 2026-04-15; results through Q2 2026)
| # | Promise (first guide) | Made (locator) | By | Path | Result (locator) | Score |
|---|---|---|---|---|---|---|
| 1 | Q3 2024 net sales €6.7–7.3bn | PR-Q2-24, 2024-07-17 | Fouquet, CEO (written) | — | €7,467m (PR-Q3-24 table) | beat |
| 2 | Q3 2024 GM 50–51% | PR-Q2-24 | Fouquet, CEO (written) | — | 50.8% (PR-Q3-24) | met |
| 3 | FY2024 net sales "similar to 2023" (€27,559m) | PR-Q2-24 headline ("continues to expect"; first given before the window) | Fouquet, CEO (written) | → "around €28 billion" (PR-Q3-24) | €28,263m, +2.6% (PR-Q4-24) | met |
| 4 | Q4 2024 net sales €8.8–9.2bn | PR-Q3-24, 2024-10-15 | Fouquet, CEO (written) | — | €9,263m (PR-Q4-24) | beat |
| 5 | Q4 2024 GM 49–50% | PR-Q3-24 | Fouquet, CEO (written) | — | 51.7% (PR-Q4-24) | beat |
| 6 | Q1 2025 net sales €7.5–8.0bn | PR-Q4-24, 2025-01-29 | Fouquet, CEO (written) | — | €7,742m (PR-Q1-25) | met |
| 7 | Q1 2025 GM 52–53% | PR-Q4-24 | Fouquet, CEO (written) | — | 54.0% (PR-Q1-25) | beat |
| 8 | Q2 2025 net sales €7.2–7.7bn | PR-Q1-25, 2025-04-16 | Fouquet, CEO (written) | — | €7,692m (PR-Q2-25) | met (top) |
| 9 | Q2 2025 GM 50–53% (band widened for tariffs, PR-Q1-25 note 3) | PR-Q1-25 | Fouquet, CEO (written) | — | 53.7% (PR-Q2-25) | beat |
| 10 | Q3 2025 net sales €7.4–7.9bn | PR-Q2-25, 2025-07-16 | Fouquet, CEO (written) | — | €7,516m (PR-Q3-25) | met |
| 11 | Q3 2025 GM 50–52% | PR-Q2-25 | Fouquet, CEO (written) | — | 51.6% (PR-Q3-25) | met |
| 12 | Q4 2025 net sales €9.2–9.8bn | PR-Q3-25, 2025-10-15 | Fouquet, CEO (written) | — | €9,718m (PR-Q4-25) | met |
| 13 | Q4 2025 GM 51–53% | PR-Q3-25 | Fouquet, CEO (written) | — | 52.2% (PR-Q4-25) | met |
| 14 | FY2025 net sales €30–35bn | PR-Q3-24, 2024-10-15 | Fouquet, CEO (written) | kept (PR-Q4-24, PR-Q1-25) → "around 15%" growth (PR-Q2-25) | €32,667m (PR-Q4-25) | met |
| 15 | FY2025 GM 51–53% | PR-Q3-24 | Fouquet, CEO (written) | → "around 52%" (PR-Q2-25) | 52.8% (PR-Q4-25) | met |
| 16 | Q1 2026 net sales €8.2–8.9bn | PR-Q4-25, 2026-01-28 | Fouquet, CEO (written) | — | €8,767m (PR-Q1-26) | met |
| 17 | Q1 2026 GM 51–53% | PR-Q4-25 | Fouquet, CEO (written) | — | 53.0% (PR-Q1-26) | met (top) |
| 18 | Q2 2026 net sales €8.4–9.0bn | PR-Q1-26, 2026-04-15 | Fouquet, CEO (written) | — | €9,326.5m (FS-Q2-26) | beat |
| 19 | Q2 2026 GM 51–52% | PR-Q1-26 | Fouquet, CEO (written) | — | 54.0% (FS-Q2-26) | beat |
| 20 | 2025 revenue "between approximately €30 billion and €40 billion" | ID-2022, 2022-11-10 | Wennink, CEO (departed) & Dassen, CFO | cut to "the lower half" in PR-Q3-24 | €32,667m | met (lower half), departed |
| 21 | 2025 GM "between approximately 54% and 56%" | ID-2022 | Wennink (departed) & Dassen | walked back by the successor CEO in PR-Q3-24: "We expect a gross margin between 51% and 53%, which is below the range we then provided, mainly related to the delayed timing of EUV demand" | 52.8% | withdrawn (successor: Fouquet from 2024-04-24) |
| 22 | €12.0bn buyback by 2025-12-31 ("We intend to repurchase shares up to an amount of €12.0 billion") | ID-2022 | company (written); Wennink (departed) & Dassen presenting | PR-Q3-25: "ASML does not expect to complete the €12 billion share buyback program in full within the 2022–2025 timeframe." | PR-Q4-25: "This program finished in December 2025, having repurchased a total of €7.6 billion out of the up to €12 billion program." — 63% | missed (flagged in advance, one quarter before the deadline) |
| 23 | Capacity: "We plan to increase our annual capacity to 90 EUV and 600 DUV systems (2025-2026)" | ID-2022 | Wennink (departed) & Dassen | not restated in any 2024–26 release read | Q2 2026 call (Dassen): ~65 low-NA EUV and ~130 immersion shipments in 2026 | withdrawn — no explicit retraction found in the filings read; capacity was sized down to demand. Read with care: a plan cut to demand is not a delivery failure |
Open (not scored): FY2026 first guide €34–39bn, GM 51–53% (PR-Q4-25) → €36–40bn, GM 51–53% (PR-Q1-26) → €43–45bn, GM 54–56% (PR-Q2-26) — two raises, tracking a beat against the first guide; Q3 2026 €11–12bn / 55–57% (PR-Q2-26; results due mid-October); the 2026–2028 buyback of up to €12bn (PR-Q4-25) — €1.1bn in Q1 (PR-Q1-26) and ~€1.1bn in Q2 (PR-Q2-26), cash-flow line "Purchase of treasury shares" €2,077.5m for H1 2026 (FS-Q2-26), against a straight-line pace of €1.0bn a quarter: on pace; the 2030 range €44–60bn / GM 56–60%, first given by Wennink/Dassen in ID-2022, confirmed by Dassen in ID-2024 ("we expect annual revenue between approximately €44 billion and €60 billion with gross margin between approximately 56% and 60% by 2030.") and restated by Fouquet on the Q3 2025 video. One wobble worth recording: PR-Q1-25 said "Our conversations so far with customers support our expectation that 2025 and 2026 will be growth years."; PR-Q2-25 retreated to "Therefore, while we still prepare for growth in 2026, we cannot confirm it at this stage."; PR-Q3-25 restored "We do not expect 2026 total net sales to be below 2025." The 2026 guide now implies +32% to +38%.
Also recorded, spoken only: on the Q2 2025 call Dassen conceded the FY2025 EUV growth view had come down — "At the beginning of the year, that percentage was a little bit higher." (speaker label Roger J. M. Dassen, call 2025-07-16) — about 40% to about 30%, explained as revenue moving from system sales to upgrades within Installed Base. Not scored (never a written guide), noted as a small revision.
Tally. 23 scored rows: 7 beat, 13 met, 1 missed, 2 withdrawn. The current CEO/CFO pair made 19 rows on their own (rows 1–19): 7 beat, 12 met, none missed. Rows 20–23 are the 2022 plan — the CEO who co-presented it has departed; the CFO who co-presented it is still CFO. Of those four, one met (revenue, lower half), one withdrawn by the successor (2025 margin), one missed (buyback, 63% executed, pre-announced), one withdrawn without a statement found (capacity).
Dodge-log roll-up (from the transcript section below): 7 dodges or declines logged over the three analyst calls with Q&A read or searched (the videos have no Q&A; 2027-guidance declines on 2026-07-15 not counted). One topic recurs: how much of next year's (or the year after's) volume is already on order — declined on 2025-04-16 (Q1 2025), 2025-07-16 (Q2 2025) and 2026-07-15 (Q2 2026) — three of three. It is a topic management itself guided (2026 as a growth year; 2027 "close to being fully covered"; a 2028 capacity step "investigated" on customer signals), and ASML stopped publishing quarterly bookings after 2025, as it announced in January 2025 ("we will continue to report bookings on a quarterly basis through 2025 but will no longer report on bookings thereafter.", Dassen, call 2025-01-29). The refusals are consistent with a disclosed policy rather than evasive — but the policy removed the number that would check the 2028 plan, and the only substitute is the annual backlog figure in the January release.
Verdict: reliable. The team in charge delivered inside or above every quarterly and annual range it gave from mid-2024 to mid-2026 (19 of 19); the margin beats cluster in Installed Base upgrades, which the company itself names as the swing factor. It is not scored conservative because the long-range record the CFO co-signed in 2022 missed on margin, buyback and capacity, and because the out-year commitments (2028 capacity, 2030 range) now rest on order coverage management declines to quantify. S7's valuation base case is not haircut.
S2 — capital allocation
XBRL us-gaap, fiscal years, €m. FCF = OCF − purchase of PP&E − purchase of intangibles (ASML's own non-GAAP definition, 20F-FY25 Item 5 footnote; its FY2024 figure €9.1bn matches Dassen on the 2025-01-29 call).
| FY | OCF | Capex (PP&E) | Intangibles | FCF | Acquisitions (net of cash) | Other investments | Buybacks | Dividends | Debt issued | Debt repaid | SBC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | 10,845.8 | 900.7 | 39.6 | 9,905.5 | 0.0 | — | 8,560.3 | 1,368.3 | 0.0 | 12.1 | 117.5 |
| 2022 | 8,486.8 | 1,281.8 | 37.5 | 7,167.5 | 0.0 | — | 4,639.7 | 2,559.8 | 495.6 | 516.2 | 68.9 |
| 2023 | 5,443.4 | 2,155.6 | 40.6 | 3,247.2 | 33.6 | 0.0 | 1,000.0 | 2,348.3 | 997.8 | 752.8 | 134.8 |
| 2024 | 11,166.2 | 2,067.2 | 15.9 | 9,083.1 | 0.0 | 0.0 | 500.0 | 2,452.9 | 22.5 | 25.7 | 172.6 |
| 2025 | 12,658.5 | 1,573.6 | 57.6 | 11,027.3 | 0.0 | 1,302.2 | 5,950.0 | 2,550.3 | 754.2 | 1,066.7 | 202.3 |
| 5 yr | 48,600.7 | 7,978.9 | 191.2 | 40,430.6 | 33.6 | 1,302.2 | 20,650.0 | 11,279.6 | 2,270.1 | 2,373.5 | 696.1 |
Tags: NetCashProvidedByUsedInOperatingActivities, PaymentsToAcquirePropertyPlantAndEquipment, PaymentsToAcquireIntangibleAssets, PaymentsToAcquireBusinessesNetOfCashAcquired, PaymentsToAcquireOtherInvestments, PaymentsForRepurchaseOfCommonStock, PaymentsOfOrdinaryDividends, ProceedsFromIssuanceOfLongTermDebt / ProceedsFromIssuanceOfDebt, RepaymentsOfLongTermDebt / RepaymentsOfDebtAndCapitalLeaseObligations, ShareBasedCompensation. The 2025 "other investments" line of €1,302.2m is the equity stake taken as lead investor in Mistral AI's Series C — Dassen on the Q3 2025 video: "approximately an 11% share in Mistral" is his figure; the identification of the line with that deal is this run's reading (FS-Q2-26 shows "Purchase of equity investment" €1,210.0m in Q3 2025) [inference].
Where the cash went. Of €40.4bn of five-year FCF, €31.9bn (79%) went back to shareholders — €20.65bn of buybacks and €11.28bn of dividends. Acquisitions were negligible (€33.6m). Debt was roughly rolled, not grown: €2.27bn raised, €2.37bn repaid. Capex ran 4.8–7.8% of sales and peaked in 2023–24 on the capacity build; the next step is the new Eindhoven campus, "We expect to break ground this year on a new campus" (Dassen, call 2026-07-15), which he places beyond 2028 for output — a capex line to watch, not yet in these numbers.
Balance sheet. Debt €4,390.9m at 2025-12-31 (LongTermDebtNoncurrent €2,709.0m + LongTermDebtCurrent €1,681.9m) against cash €12,916.0m and short-term investments €405.9m → net cash ~€8.9bn. H1 2026 repaid a further €693.2m (FS-Q2-26); long-term debt €1,984.4m at 2026-06-28. This closes the net-debt gap the 2026-09-21 dossier left open.
SBC and the share count. SBC €696.1m over five years, 0.3–0.6% of sales and 1.0–4.2% of FCF — immaterial. Buybacks did far more than offset it: shares outstanding 416,514,034 (2020) → 385,417,665 (2025), diluted weighted average 419.1m → 388.9m (CommonStockSharesOutstanding, WeightedAverageNumberOfDilutedSharesOutstanding), −7.2%.
Buybacks at what price. 20F-FY25 Note 22: "In 2025, we repurchased 8,323,320 shares (2024: 574,925 shares) for a total consideration of €5,950.0 million" — the purchase table's total line averages €714.86. Five years: €20,650.0m over ~33.4m shares (XBRL TreasuryStockSharesAcquired; 2023 summed from the monthly facts) → ~€618 per share. Against ~€1,533.5 today that is ~2.5x the average price paid (2025's purchases ~2.1x). The buying was lumpy and not price-disciplined in either direction — €8.56bn in 2021 near the prior cycle peak [background: the 2021 price level], €0.5bn in 2024, then €5.95bn in 2025 at €583–934 — but every tranche is under water only in the sense of being well in the money.
What the bonus is paid on. Not EPS. The 2025 STI's financial metric is "EBIT Margin % (non-GAAP measure), measuring Income from operations as percentage of total net sales" plus non-financial targets; the LTI pays on relative TSR, ROAIC, a Technology Leadership Index and ESG (20F-FY25 Remuneration report, "Short-term incentive 2025" and "Step 4"); the 2023–2025 LTI used a normalised cash-conversion rate. No EPS-plus-buyback flag.
Returns. NOPAT = income from operations × (1 − effective tax rate), tax rate from IncomeTaxExpenseBenefit ÷ pre-tax income. Invested capital two ways, both year-end: (a) financing — equity + all debt − cash − short-term investments; (b) operating, ASML's own ROAIC denominator (total assets − cash − short-term investments − total current liabilities − non-current contract liabilities, 20F-FY25 LTI definition), from Assets, LiabilitiesCurrent, ContractWithCustomerLiabilityNoncurrent.
| FY | Op. income | Tax rate | NOPAT | IC (financing) | ROIC (a) | IC (operating) | ROIC (b) |
|---|---|---|---|---|---|---|---|
| 2020 | 4,051.5 | 13.7% | 3,495.2 | 11,192.0 | 31.2% | 11,672.4 | 29.9% |
| 2021 | 6,750.1 | 15.2% | 5,721.9 | 7,134.4 | 80.2% | 7,117.0 | 80.4% |
| 2022 | 6,500.7 | 15.0% | 5,524.1 | 5,695.2 | 97.0% | 5,670.9 | 97.4% |
| 2023 | 9,042.3 | 15.8% | 7,613.0 | 11,073.9 | 68.7% | 11,847.2 | 64.3% |
| 2024 | 9,022.6 | 18.6% | 7,345.7 | 10,423.1 | 70.5% | 10,171.5 | 72.2% |
| 2025 | 11,301.4 | 17.7% | 9,306.5 | 10,681.2 | 87.1% | 9,614.5 | 96.8% |
Incremental ROIC, endpoints stated: NOPAT €3,495.2m (2020) → €9,306.5m (2025), +€5,811.3m; invested capital €11,192.0m → €10,681.2m on (a), −€510.8m, and €11,672.4m → €9,614.5m on (b), −€2,057.9m. NOPAT nearly tripled while invested capital fell — the incremental return is not a finite number; customer down payments (contract liabilities €5,594.1m → €19,372.6m, ContractWithCustomerLiability) financed the growth. market data's own ratio, on a broader denominator, is 35.1% (FY2024) and 38.8% (FY2025) (get_profitability_ratios; free tier returns two years only). Return on equity 50.5% in FY2025 (same source).
What the acquisitions were worth. Goodwill €4,629.1m (2020) → €4,588.6m (2025), unchanged since 2023; GoodwillImpairedAccumulatedImpairmentLoss 0 in every year 2021–2025; intangible impairments €6.5–11.1m a year. No write-down of any acquisition in the window.
Verdict: compounds. Near-zero M&A, 79% of FCF returned, a shrinking share count, net cash, and returns on capital that rose as the capital base shrank. The one judgement to watch is the Mistral stake — €1.3bn outside the core, the first non-trivial investment of its kind in the window.
Earnings quality
- Non-GAAP bridge — none to test; clean. ASML reports US GAAP as its primary standard and the quarterly releases carry no adjusted EPS, no add-backs and no "one-off" exclusions (PR-Q2-24 to PR-Q2-26, headline tables all US GAAP). Its non-GAAP measures are definitional — FCF, EBIT margin, ROAIC — not adjusted profit. The one reconciliation that exists runs the other way: the statutory IFRS accounts capitalise development spending that US GAAP expenses — PR-Q4-25, "US GAAP and IFRS Financial Reporting": "The most significant recurring differences between US GAAP and IFRS that affect ASML concerns the capitalization of certain product development costs, valuation of equity investments, and accounting for income taxes." The US GAAP book this pipeline reads is the more conservative of the two. "No adjustments reported" is the finding.
- SBC — clean. €202.3m in 2025: 0.62% of sales, 1.8% of FCF (XBRL
ShareBasedCompensation). FCF after SBC is 98% of FCF. - Cash conversion — clean over three years, negative in H1 2026. OCF/NI 0.69 (2023), 1.47 (2024), 1.32 (2025); three-year €29,268.1m over €25,020.0m = 1.17. Accruals ((NI − OCF) / average total assets): +6.3% (2023), −8.1% (2024), −6.2% (2025). The half-year shape is extreme and is timing: Q4 2025 OCF €11,410.3m, Q1 2026 −€2,185.6m, Q2 2026 €1,703.0m; H1 2026 OCF −€482.5m against net income €5,674.3m (FS-Q2-26). The Q4 2025 figure carries the down payments on record Q4 bookings of €13.2bn (PR-Q4-25). Read the year, not the half.
- Working capital — one flag. Annual: DSO 57.4 (2023) → 57.8 (2024) → 33.8 days (2025); DIO (inventory over cost of sales) 240.7 → 288.7 → 270.7 days; inventory 32.1% → 38.5% → 35.0% of sales (
AccountsReceivableNetCurrent,InventoryNet). No two-period rise on the annual series. Quarterly, receivables have risen two quarters running while sales grow: €3,023.0m (2025-12-31) → €4,402.9m → €7,252.6m (2026-06-28), i.e. ~28 → ~46 → ~71 days on annualised quarterly sales, against ~59 days at 2025-06-29 (FS-Q2-26 quarterly balance sheet). Part of it is ASML's known Q4 collection peak (Dassen on 2025-01-29: FY2024 Q4 FCF with "the majority of cash coming in at the very end of the quarter", speaker label Roger Dassen), but the +12 days year on year at Q2 is not seasonal. It is the flag. Inventory is flat at €11.4–11.8bn through five quarters while sales grow, and inventory reserves are charged every quarter (€80–172m, FS-Q2-26 cash-flow line) — no flag. - Costs moved onto the balance sheet — clean. US GAAP expenses development (point 1); intangibles fell €1,048.9m → €485.8m (2020–2025,
IntangibleAssetsNetExcludingGoodwill); purchased intangibles €15.9–57.6m a year; capex fell from 7.3% to 4.8% of sales in 2025. Interest capitalised is not separately tagged; interest expense €118.3m in 2025 (InterestExpenseNonoperating). - Sector equivalent. For an equipment maker the analogue is the customer-prepayment cushion: non-current contract liabilities fell €5,625.4m → €3,366.3m in 2025 while current ones rose €12,570.8m → €16,006.3m — down payments moving toward delivery. A fall in total contract liabilities (€19,372.6m at 2025-12-31) would reverse part of the cash conversion above; it is the number that ties earnings quality to the order-coverage thread in S8.
EQ: 1 flag — receivables up two quarters running (~28 → ~46 → ~71 days, +12 days YoY at Q2 2026) while sales grow; no non-GAAP add-backs (US GAAP only), SBC 1.8% of FCF, 3-yr OCF/NI 1.17.
Transcripts (read this run; the 2026-09-21 dossier had none)
The archive holds eight market data files. Read this run: FY2026-Q2 (call 2026-07-15) in full and FY2025-Q2 (call 2025-07-16) in full; FY2026-Q1 (2026-04-15) and FY2025-Q3 (2025-10-15) in full — both are results videos with IR-scripted questions and no analyst Q&A; FY2025-Q4 (2026-01-28) is the press conference for media, not the analyst call, and was read only for its opening; FY2024-Q3, FY2024-Q4 and FY2025-Q1 were read for the CFO section and searched for refusals, not read in full. Speaker labels are names only; roles from 20F-FY25 as above. Safe-harbor text skipped.
FY2026-Q2 — call 2026-07-15 (Fouquet, Dassen)
CFO section — the changes, not the restatement. Q3 2026 guided €11–12bn, GM 55–57%; FY2026 raised to €43–45bn, GM 54–56% (from €36–40bn / 51–53% in April). Low-NA EUV ~65 units in 2026; immersion ~130; non-EUV systems +~25%; Installed Base +30%+; China "around 20%" of 2026 sales. Capacity: "For 2027, we are now close to being fully covered with orders for Low-NA EUV, and we are planning to increase our Low-NA EUV capacity by around 30%." (Roger Dassen) — and a further 30% "investigated" for 2028 on both EUV and immersion. Opex over guidance in Q2 on the technology/IT transformation costs. Buyback ~€1.1bn in the quarter; €1.88 interim dividend.
What analysts asked about (grouped): pricing power (Bouvignies, UBS; Caso, Wolfe; van Putten, Morgan Stanley) — whether value-based pricing lets Low-NA prices rise; the 2027/2028 capacity steps and their order cover (Bouvignies; Quatrochi, Wells Fargo; Sankar, TD Cowen; Houri, ODDO BHF; Caso); mix and 2026 exit margin (Scemama, BofA; Sankar); 2027 margin and operating leverage (Scemama; CJ Muse, Cantor); Installed Base upgrades (van Putten); WFE comparison (Qiu, Berenberg); High-NA insertion, DRAM vs logic (Qiu; Hosseini, Susquehanna; Muse). The weight of the call was on whether the 2028 step is real.
The single most useful answer: Sankar asked whether ASML waits for purchase orders before adding capacity. Dassen: "Of course, we don't have orders for 110 EUV Low-NA at this stage." — the 2028 step is pre-emptive, built on demand signals that "have not yet translated into full POs".
Dodges and declines.
- Houri (ODDO BHF) — how much of the 110-unit 2028 scenario is covered by orders → declined by policy: "We're not sharing order intakes. I'm not going to give you the coverage number" (Roger Dassen).
- Bouvignies (UBS) — when better Low-NA pricing shows up → answered a different question (it depends on lead times): "That really depends on the order situation that you have with customers." (Roger Dassen). A dodge on timing.
- Qiu (Berenberg) — whether ASML outgrows WFE in 2027–28 → "Tammy, as you know, we never comment on WFE." (Roger Dassen). Policy decline.
- Scemama, van Putten, Muse — 2027 gross margin, 2027 revenue, incremental operating margin → declined to guide beyond the year ("Of course, I'm not going to guide you the gross margin for next year, Krish", Roger Dassen, to Sankar) while describing each driver as positive. Consistent with the one-year guiding practice; logged as a decline, not a dodge.
FY2025-Q2 — call 2025-07-16 (Fouquet, Dassen)
CFO section. Q3 2025 €7.4–7.9bn, GM 50–52%; FY2025 "around 15%" growth, GM ~52%; 2026 growth "cannot confirm"; backlog ~€33bn after a China adjustment; ~€1.4bn buyback in the quarter, €5.8bn cumulative on the 2022–2025 programme.
What analysts asked about: what changed on 2026 in 90 days (Quatrochi; Muse; Qiu) — tariffs and the 232 review, per management; EUV growth coming down from ~40% to ~30% (Bouvignies; Muse); China strength and pull-forward (Scemama; Caso); bookings needed for 2026 (Sankar; Metuku, HSBC); the €1.4bn backlog adjustment (Metuku) — answered plainly: "that has led to the debooking or the cancellation of orders for about EUR 1.4 billion." (Roger J. M. Dassen), all China, mostly DUV.
Dodges and declines.
- Sankar (TD Cowen) — bookings run-rate needed to call 2026 a growth year → "Yes, Krish, very nice try. I think some tried this before. We're not going there, right?" (Roger J. M. Dassen).
- Metuku (HSBC) — whether ~€6bn of H2 orders sets up a flat 2026 → "I'm not going to give you a grade on your math, Adithya." (Roger J. M. Dassen).
- Scemama (BofA) — how much of China's strength is pull-ahead of further restrictions → answered on demand level instead: "And exactly what is driven by considerations by customers, it's very hard to tell." (Roger J. M. Dassen). A dodge.
FY2025-Q1 — call 2025-04-16 (searched for refusals only)
- Sankar (TD Cowen) — bookings run-rate needed for 2026 growth → "In terms of what bookings do we need to get there, I'm not going to go into any detail there." (Roger Dassen), pointing to the backlog instead.
FY2026-Q1 (2026-04-15) and FY2025-Q3 (2025-10-15) — results videos
No analyst Q&A, so no dodges can occur. Guidance content is in the S8 table (FY2026 to €36–40bn — "we are actually narrowing the window and also increasing the window of our expectation to EUR 36 billion to EUR 40 billion for this year.", R.J.M. Dassen; 2030 range restated by Christophe Fouquet). Note for the next run: ASML alternates analyst calls (Q2, Q4) with scripted videos (Q1, Q3) in this archive; a "two most recent transcripts" read therefore gets one real Q&A at most.
Full notes, 21 Sep 2026 13 min read
ASML — dossier, 2026-09-21
Slot names-ai-capex-3. Model-drafted unattended by the cloud research routine; nothing here is human-verified. Sources and locators are in relationships.yaml; figures below carry theirs inline. Anything from background knowledge is marked [background].
Price reference: $1,714.68 close, 2026-09-21 (market data get_latest_stock_price NASDAQ:ASML; volume 888,401 shares, so roughly $1.52bn traded that day). EUR/USD 1.14673 on the same date (market data get_latest_forex_price FX:EURUSD) — every conversion below uses that one rate and is marked as a conversion. ASML reports in euro; the US listing is one ordinary share per ADS [background].
Shares outstanding 385,417,665 at 2025-12-31 (20-F XBRL CommonStockSharesOutstanding) → market capitalisation ~$660.9bn / ~€576.3bn.
This is a foreign private issuer. Under the skill's §3 table that means: 20-F Item 3.D risk factors and Item 5 in place of a 10-K, the latest 6-K results in place of a 10-Q, proxy skipped (not filed) and insider pattern skipped (no Form 4). The EDGAR history is 25 20-Fs and 361 6-Ks; there is no 10-K, no DEF 14A and no Form 4 to read.
S1 — Source
watchlist (owner, Apple Stocks, 2026-09-20), cluster ai_semis, coverage sec_fpi, cik 937966. No Tier 0 promotion.
S2 — Kill test
All figures in EUR from the 20-F XBRL company facts (data.sec.gov/api/xbrl/companyfacts, CIK 0000937966).
| FY | Net sales €m | Gross profit €m | GM % | Op income €m | Op margin % | Net income €m | Net margin % | R&D €m | Diluted WA shares m |
|---|---|---|---|---|---|---|---|---|---|
| 2020 | 13,978.5 | 6,797.2 | 48.6 | 4,051.5 | 29.0 | 3,553.7 | 25.4 | 2,200.8 | 419.1 |
| 2021 | 18,611.0 | 9,809.0 | 52.7 | 6,750.1 | 36.3 | 5,883.2 | 31.6 | 2,547.0 | 410.4 |
| 2022 | 21,173.4 | 10,700.1 | 50.5 | 6,500.7 | 30.7 | 5,624.2 | 26.6 | 3,253.5 | 398.0 |
| 2023 | 27,558.5 | 14,136.1 | 51.3 | 9,042.3 | 32.8 | 7,839.0 | 28.4 | 3,980.6 | 394.1 |
| 2024 | 28,262.9 | 14,492.0 | 51.3 | 9,022.6 | 31.9 | 7,571.6 | 26.8 | 4,303.7 | 393.6 |
| 2025 | 32,667.3 | 17,258.0 | 52.8 | 11,301.4 | 34.6 | 9,609.4 | 29.4 | 4,698.8 | 388.9 |
Quarterly, the two most recent (Q2 2026 6-K press release, 2026-07-15):
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Total net sales €m | 8,767 | 9,326 |
| of which Installed Base Management €m | 2,488 | 2,762 |
| New systems sold (units) | 67 | 86 |
| Used systems sold (units) | 12 | 5 |
| Gross margin % | 53.0 | 54.0 |
| Net income €m | 2,757 | 2,918 |
| Basic EPS € | 7.15 | 7.59 |
| End-quarter cash and short-term investments €m | 8,376 | 7,582 |
Backlog: remaining performance obligations €46.5bn at 2025-12-31, against €43.3bn (2024), €45.0bn (2023), €45.4bn (2022), €28.9bn (2021), €15.1bn (2020). After three flat years the backlog turned up again in 2025 — 1.4x the year's revenue.
Net debt: not computed. Cash and short-term investments were €7,582m at 2026-06-30 (€12,916m of cash alone at 2025-12-31, before €5.95bn of 2025 buybacks worked through). ASML's outstanding eurobond debt was not read this run — the 20-F's financing appendix was not opened — so no net-debt or net-debt/EBITDA figure is stated here rather than guessed. Given €9.6bn of annual net income and a maturity profile that is not a constraint on any reading of the cash flows, this is a gap in completeness, not in the survival question.
Share count over five years — shrinking, which is rare in this cluster. 419.1m diluted weighted average (2020) → 388.9m (2025), −7.2%; shares outstanding 416.5m → 385.4m. €5.95bn repurchased in 2025 and €1.1bn in Q2 2026 under a 2026–2028 programme, plus a €1.88 interim 2026 dividend paid 2026-08-05. Of the three names in this slot, ASML is the only one where the count goes down.
Analyst coverage: not obtained (no transcript was reachable — see S3).
Verdict — survives outright, and is the highest-quality balance sheet in this slot. A 52.8% gross margin and a 29.4% net margin on €32.7bn, six straight profitable years through a semiconductor downturn, €46.5bn of backlog and a shrinking share count. Nothing here threatens solvency. The kill question for ASML is not financial — it is political: 29.1% of sales go to a country whose access to the product is decided by three governments, none of them ASML's customer.
S3 — Filings, gate-minimum (FPI variant)
Read this run: the FY2025 20-F (Item 3.D risk factors in full heading form and four risk factors in body, Item 5 financial performance and MD&A, geographic and customer concentration), the Q2 2026 6-K press release (results, guidance, capacity, buyback), and the investor-relations presentation filed with it. Not read: any transcript. Equibles has no speaker-labelled transcript on file for ASML FY2026 Q2, and the fool.com fallback URL for that date returned 404. The gate-minimum spec asks for two transcripts; zero were obtained, and every forward statement below therefore comes from the written 6-K rather than from Q&A. That is this name's thin evidence.
The three biggest risks management itself discloses
- Export controls decide what can ship, and ASML does not control the process. "under Dutch, US and other applicable laws, we are required to secure export licenses for EUV systems, specific DUV immersion systems, and some of our other products." The same risk factor adds that US measures impose "license requirements for the sale or transfer of US-origin items, as well as limitations on support by US persons for non-US origin items destined for advanced-node fabs in China" and that ASML does "not control the licensing process or approval criteria." One specific, dated exposure sits inside the next twelve months: the US 50%-ownership affiliate rule "has been suspended for one year, until November 10, 2026, as part of a trade agreement with China." A suspension, not a repeal.
- Customer concentration, and it got worse in 2025. "Total net sales to our largest customer amounted to €7,796.7 million, or 23.9% of total net sales in 2025, compared with €4,682.4 million, or 16.6% of total net sales in 2024. In 2025, 38.0% of total net sales were made to our two largest customers." Seven points of concentration added in a single year. ASML does not name the customers.
- Cyclicality and geographic exposure. The risk factor list opens with "The semiconductor industry can be cyclical, and we may be adversely affected by any downturn", and the international-operations factor puts a number on where the cycle sits: "Customers in China represented 29.1% of our 2025 total net sales and 36.1% of our 2024 net sales." Competition is named concretely — "We compete primarily with Canon and Nikon in respect of DUV systems" — and separately against Applied Materials and KLA-Tencor, which is worth recording because AMAT is in the same watchlist cluster and the 2026-09-20 cluster file places it purely as a supplier to the chain, not as a competitor to another member.
Latest quarter and guidance
Q2 2026 came in above guidance on both lines — €9.3bn of sales and 54.0% gross margin — "driven primarily by higher than expected Installed Base Management sales", i.e. service and field upgrades rather than new systems. Guidance:
- Q3 2026: €11.0–12.0bn of net sales, 55–57% gross margin, R&D ~€1.2bn, SG&A ~€0.4bn.
- FY2026 raised to €43–45bn of net sales, 54–56% gross margin. Against €32.7bn in 2025 that is +32% to +38%.
- Next Capital Markets Day 2027-06-10, where the longer-term view will be updated.
The most important sentence in the filing is about capacity, not revenue. "we are planning to add 30% to our 2026 low NA EUV capacity of around 65 for 2027, and we are investigating to increase capacity with another 30% for 2028. Similarly, we plan to add 30% to our 2026 DUV immersion capacity of around 130 for 2027." The 2026-09-20 cluster pass argued that TSMC's capacity discipline is the best single bubble indicator for this complex, and flagged that TSMC is absent from the watchlist. This is the same indicator one layer up the chain, published quarterly, from a name that is on the watchlist. The monopolist at the bottleneck is choosing to remove the bottleneck.
Proxy, insider pattern
Skipped — not filed. FPIs file no DEF 14A and their insiders file no Form 4, so there is no insider-ownership percentage, no compensation structure and no insider transaction pattern for this name. This is a structural gap in coverage for every sec_fpi row on the watchlist, not a gap in this run. Dutch remuneration and shareholding disclosure exists in the annual report; it was not extracted.
Red-flag sweep
- Auditor change / restatement: nothing in the EDGAR index (no 20-F/A, no NT 20-F). The
efts.sec.govfull-text sweep was not run (time). - Going concern: not applicable on these numbers; not checked with the tool (Equibles budget).
- Executive changes: not checked.
- Customer concentration: read from the 20-F directly, quoted above.
- Unresolved staff comments: Item 4A is "Not applicable" — the SEC has no open comments on this issuer. ASML's last CORRESP exchange was 2020.
S5 — Ownership
⚠️ 3spread does not cover this name. threespread.py holders ASML (CUSIP N07059202) returned 2 filers and 1,185 shares, against Equibles' 2,504 institutions and 86.0m shares. The skill routes all of S5 through 3spread; for ADR and other foreign CUSIPs it answers near-empty rather than erroring. Slot names-ai-capex-2 found exactly this for ARM and OMAB. Three confirmations now — this should be treated as a known tool limitation, not re-discovered a fourth time.
Top institutional holders, 13F report date 2026-06-30 (Equibles GetTopHolders; 2,595 rows across 2,504 institutions, 86,026,133 shares, $171.1bn):
| # | Institution | Type | Shares | $m | % of inst. total |
|---|---|---|---|---|---|
| 1 | FMR LLC | Common | 5,478,341 | 10,898.8 | 6.37% |
| 2 | Fisher Asset Management | Common | 4,737,614 | 9,425.2 | 5.51% |
| 3 | Capital World Investors | Common | 3,726,679 | 7,414.0 | 4.33% |
| 4 | Invesco | Common | 3,140,208 | 6,247.3 | 3.65% |
| 5 | State Farm Mutual Automobile Insurance | Common | 2,758,173 | 5,487.2 | 3.21% |
| 6 | Van Eck Associates | Common | 2,459,420 | 4,892.9 | 2.86% |
| 7 | Capital International Investors | Common | 2,439,219 | 4,852.7 | 2.84% |
| 8 | JPMorgan Chase | Common | 2,395,859 | 4,766.4 | 2.79% |
| 9 | T. Rowe Price | Common | 1,933,524 | 3,846.6 | 2.25% |
| 10 | Susquehanna International Group | Put | 1,836,900 | 3,654.4 | 2.14% |
| 11 | Morgan Stanley | Common | 1,788,291 | 3,557.7 | 2.08% |
| 12 | Bank of America | Common | 1,662,192 | 3,306.8 | 1.93% |
Note that the 86.0m institutionally reported shares are 22% of the 385.4m outstanding — the rest sits in Amsterdam, outside 13F reporting, so this table is the US slice and not the register.
Two things stand out. Fisher Asset Management at number two is an independent RIA rather than an index complex — an active, concentrated holder near the top of a €576bn company. And row 10 is a put, not a holding: Susquehanna carries a 1,836,900-share notional bearish options position, the only such line in the top twelve.
13D/G: three filings in the whole history, all 13G/A, newest 2025-04-23. No 13D, no activist.
Insider ownership: not available (FPI — see S3).
Short interest (Equibles, FINRA): 1,284,921 (2026-07-15) → 1,068,098 → 1,352,364 → 1,524,269 (2026-08-31), days to cover 1.0–1.4. Against 385.4m shares that is 0.4% of shares outstanding — effectively nobody is short the ADR. The tool's 2026-09-15 estimate (~1.60m) is a model output, not FINRA data. The organised bearish expression here is Susquehanna's put line, not stock borrow.
Shelf, ATM, buyback: the question is inverted for this name. No shelf or ATM (an FPI issues under Dutch corporate authority, not an S-3 [background]). Capital flows the other way: €5.95bn repurchased in 2025, ~€1.1bn in Q2 2026 under the 2026–2028 programme, plus an interim 2026 dividend of €1.88 per ordinary share paid 2026-08-05. Nothing hangs over the stock.
Who is on the other side: large active managers, an index tail, and one options desk with a put. There is no crowded short and no activist. What is on the other side of this trade is a government licence and a multiple.
S8 — Valuation and sizing (proposed only; owner-only items OPEN)
At $1,714.68 with 385.4m shares: market capitalisation ~$660.9bn / ~€576.3bn (converted at EUR/USD 1.14673).
Against FY2025: 17.6x EV-free price/sales, 60.0x net income (€576.3bn / €9,609.4m). Basic EPS was €24.73, or $28.36 converted, so the trailing P/E on the traded ADR is 60.5x.
Out-year model. FY2026 is management's own guide; FY2027–28 are built from the capacity additions management has announced (+30% low-NA EUV and DUV immersion for 2027, a further 30% "investigating" for 2028) rather than from a growth rate.
| FY2026E | FY2027E | FY2028E | |
|---|---|---|---|
| Net sales €m | 44,000 (guide €43–45bn) | 52,000 | 58,000 |
| Growth | +35% | +18% | +12% |
| Gross margin | 55% (guide 54–56%) | 56% | 56% |
| Net margin | 30.5% | 32.0% | 33.0% |
| Net income €m | 13,420 | 16,640 | 19,140 |
| Shares m | 382 | 376 | 370 |
| EPS € | €35.13 | €44.26 | €51.73 |
| EPS $ (at 1.14673) | $40.28 | $50.76 | $59.32 |
| Implied P/E at $1,714.68 | 42.6x | 33.8x | 28.9x |
| Case | Basis | Value |
|---|---|---|
| Bear — AI capex digests; 2028 sales back to €45bn at a 28% net margin, and the multiple goes to the 22x this name traded at in past downturns [background] | €34.05 EPS → $39.05 × 22 | ~$859 |
| Base — the table above at 30x FY2028 | $59.32 × 30 | ~$1,780 |
| Bull — the second +30% capacity step is taken and filled; 2028 sales €66bn at a 34% net margin, 35x | $69.60 × 35 | ~$2,436 |
The base case is ~$1,780 against $1,714.68 — about 4% of upside over three years, and it already assumes the FY2026 guide is met, the 2027 capacity addition is filled, and the margin keeps climbing. That is the same shape slot names-ai-capex-2 found at MRVL and ARM: a correct operating forecast that does not produce a return at today's price. Three names in two slots now model at or below the traded price.
⏳ Buy price and position size are owner-only and stay OPEN (user). Liquidity is not a constraint (~$1.52bn traded on 2026-09-21 on the US line alone, with the Amsterdam line on top).
S9 — Monitoring
Next earnings: Q3 2026 results, expected around 2026-10-14 — ASML reports on a strict mid-January / mid-April / mid-July / mid-October cadence (Q2 filed 2026-07-15, Q1 2026-04-15), derived from the 6-K cadence rather than a calendar feed. Capital Markets Day 2027-06-10, which the company itself names as the date the long-term view gets rewritten, is the larger event.
Filing feed: the Tier 0 EDGAR sweep covers cik 937966. For an FPI the feed is 6-Ks, and ASML files a great many of them (361 in the index) — the quarterly results 6-K is the one that matters and it is distinguishable by document name (form6-kquarterlyfilings.htm).
The leading indicator: announced capacity, not orders. ASML no longer publishes a bookings number in the quarterly release — the Q2 press release says only that "Our order intake remained extremely strong in the first half of the year" with no figure. What it does publish is planned capacity: ~65 low-NA EUV units in 2026, +30% for 2027, a further 30% "investigating" for 2028, and the same steps on DUV immersion off ~130 units. Whether the 2028 "investigating" becomes "planning" is the single most informative disclosure this company will make, because ASML adds capacity only against customer commitments and it is the one firm in the chain with no competitor to lose share to. A retreat from that second 30% would be the earliest credible signal that the AI build is topping — and it would come from the layer above TSMC, which the watchlist does not carry. Secondary: the China revenue share (36.1% → 29.1%) and the 2026-11-10 expiry of the suspended US 50%-ownership rule.
Trigger that converts this to a buy: the 2028 capacity step confirmed as planned rather than investigated, while the shares trade below ~28x the forward EPS on this model — roughly $1,140 on the FY2027E line. On the evidence in hand the business is not the question; the entry price is. The specific price and the size remain the owner's.